Emicizumab prophylaxis in current haemophilia A care in the Czech Republic—data from the Czech National Haemophilia Programme Registry

Background: Nonfactor therapy with emicizumab has become an important part of the haemophilia A treatment landscape recently. Objectives: We aimed to analyze data on the transition from previous treatment regimens to emicizumab in routine clinical practice in the Czech Republic. Methods: Retrospecti...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ester Zápotocká, Petra Ovesná, Bohumír Blažek, Zuzana Čermáková, Zdeňka Hajšmanová, Radomíra Hrdličková, Petr Birke, Daniela Procházková, Petr Smejkal, Jan Blatný
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2025-10-01
Series:	Research and Practice in Thrombosis and Haemostasis
Assuntos:	annual bleeding rate consumption emicizumab haemophilia A prophylaxis zero bleeds
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2475037925005394
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!